NOVOCURE LIMITED Financial comparisons NovoCure Limited
Equities
NVCR
JE00BYSS4X48
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.81 USD | +2.77% |
|
+5.12% | +18.85% |
| 09-03 | NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor | MT |
| 09-03 | Novocure Announces CEO Changes, Effective January 1, 2025 | CI |
Main competitors
| Revenues ($) (Y-1) | Net margin (Y-1) | Operating Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Debt/EBITDA) (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 509M | -40.65% | -45.72% | -51.52% | -17.71% | -1.48x | ||
| 730M | +20.17% | +21.79% | +24.96% | +13.31% | -1.07x | ||
| 1.06B | +8.59% | +9.57% | +7.52% | +5.59% | -1.1x | ||
| 2.05B | +3.98% | +15.28% | - | - | - | ||
| 3.08B | +7.58% | +11.48% | +7.80% | +4.74% | 1.44x | ||
| 633M | +14.55% | +20.01% | +10.40% | +10.76% | -0.77x | ||
| 232M | +32.35% | +36.86% | +30.19% | +22.21% | - | ||
| 1.12B | +30.05% | +36.30% | +22.45% | +15.43% | - | ||
| 494M | -0.33% | -0.48% | +2.27% | +1.70% | -13.8x | ||
| 375M | +8.22% | +11.80% | - | - | -1.57x | ||
| 288M | +17.46% | +16.59% | +14.31% | +9.46% | - | ||
| 180M | +8.75% | +10.20% | +2.81% | - | - | ||
| 1.55M | -1,686.36% | -1,551.14% | - | - | 4.35x | ||
| 60.23M | +33.46% | +41.48% | +24.90% | +20.42% | -1.57x | ||
| 512M | -30.49% | +15.82% | +2.07% | +0.47% | 4.03x | ||
| 64.72M | +28.20% | +25.47% | +4.87% | - | - | ||
| 139M | -31.20% | -33.79% | -32.38% | - | 7.51x | ||
| 867M | -45.38% | +7.13% | - | - | - | ||
| 88.28M | +32.81% | +38.90% | +49.68% | +34.20% | -1.08x | ||
| Average | 657M | -83.59% | -69.08% | +8.02% | +10.05% | -0.43x | |
| Weighted average by Cap. | 1.01B | -19.88% | -13.11% | +13.24% | +10.03% | -1.19x |
- Stock Market
- Equities
- NVCR Stock
- Sector NovoCure Limited
- Financial comparisons
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition